dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Adamo, Barbara |
dc.contributor.author | Pascual, Tomás |
dc.contributor.author | Vidal, Maria |
dc.contributor.author | Pérez Fidalgo, José A |
dc.contributor.author | Gómez Pardo, Patricia |
dc.contributor.author | Paré, Laia |
dc.contributor.author | Bellet Ezquerra, Meritxell |
dc.date.accessioned | 2020-07-08T12:04:08Z |
dc.date.available | 2020-07-08T12:04:08Z |
dc.date.issued | 2019-09-18 |
dc.identifier.citation | Adamo B, Bellet M, Paré L, Pascual T, Vidal M, Pérez Fidalgo JA, et al. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial. Breast Cancer Res. 2019 Sep 18;21(1):108. |
dc.identifier.issn | 1465-542X |
dc.identifier.uri | https://hdl.handle.net/11351/5073 |
dc.description | Càncer de mama; Quimioteràpia metronòmica; Vinorelbina |
dc.description.sponsorship | This study was supported by a grant from Pierre-Fabre. Pierre-Fabre had no role in the management of this trial. The decisions and responsibilities of this trial were all under the sponsor: SOLTI Group. |
dc.language.iso | eng |
dc.publisher | Springer Nature |
dc.relation.ispartofseries | Breast Cancer Research;21(1) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Marcadors tumorals |
dc.subject | Medicaments antineoplàstics |
dc.subject | Mama - Càncer - Tractament |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | Biomarkers, Tumor |
dc.subject.mesh | Vinorelbine |
dc.subject.mesh | /drug therapy |
dc.title | Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1186/s13058-019-1195-z |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | marcadores tumorales |
dc.subject.decs | vinorelbina |
dc.subject.decs | /tratamiento farmacológico |
dc.relation.publishversion | https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-019-1195-z |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.authoraffiliation | [Adamo B, Vidal M] Department of Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain. Translational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Barcelona, Spain. [Bellet M, Gómez-Pardo P] Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Paré L] Translational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Pascual T] Department of Medical Oncology, Hospital Clínic de Barcelona, Barcelona, Spain. Translational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Barcelona, Spain. SOLTI Breast Cancer Research Group, Barcelona, Spain. [Pérez Fidalgo JA] Hospital Clínico Universitario de Valencia, Valencia, Spain. INCLIVA Instituto de Investigación Sanitaria, Universitat de València, Valencia, Spain. Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Madrid, Spain |
dc.identifier.pmid | 31533777 |
dc.identifier.wos | 000487022700002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |